Research programme: selective androgen receptor modulators - Kaken
Alternative Names: 319767; S-40503Latest Information Update: 04 Nov 2017
At a glance
- Originator Kaken Pharmaceutical
- Class Quinolines
- Mechanism of Action Selective androgen receptor modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Cancer; Osteoporosis
Most Recent Events
- 04 Nov 2017 No recent reports of development identified for preclinical development in Cancer in Japan
- 04 Nov 2017 No recent reports of development identified for preclinical development in Osteoporosis in Japan (SC)
- 30 Jul 2007 Preclinical development is ongoing